News & Media

Home > News & Media

Blue Light Cystoscopy System Approved for Marketing in China; “Blue Light Era” for Precision Treatment of Bladder Cancer Begins

2026

2025

2024

2023

2022

2021

2020

2019

Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth

Cevira® Endorsed with Level 1A Evidence in Expert Consensus, Establishing a New Benchmark for Non-Invasive Treatment of Cervical Precancerous Lesions

Asieris and SPH Kyuan Trade Announce Import and Distribution Strategic Partnership to Accelerate the Commercialization of Cevira®

Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

February 27, 2026

Asieris Announces European Medicines Agency Accepts Marketing Authorization Application for APL-1702

January 22, 2026

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

January 8, 2026

Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

January 7, 2026

Asieris Pharmaceuticals Appoints Dr. Ningshu Liu as Chief Scientific Officer

January 3, 2026

Asieris’ APL-1202 Receives Health Canada’s Special Access Program Approval for Treatment of Free-Living Amoeba Infections